An international study demonstrating that the daily use of an HIV drug can reduce the risk of acquiring HIV, has been chosen as one of ten publications to be presented at the annual Clinical & Translational Science Awards (CTSA) steering committee meeting, October 5-6, 2011, in Bethesda, MD. The study was led by UCSF’s Robert Grant, MD, MPH and featured in The New England Journal of Medicine.
Based on the results and those of two subsequent positive studies, the Centers for Disease Control are formulating guidance on use of pre-exposure prophylaxis (PrEP) as a new HIV prevention strategy.
The study was co-authored by UCSF’s Susan Buchbinder, MD, Albert Liu, MD, Kathleen Mulligan, PhD, Furong Wang, MD, and David Glidden, PhD. Dr. Grant will present the results at the CTSA meeting, which will include leaders from the National Institutes of Health (NIH) and across the national, 60-institution CTSA network.
Support for this research was provided by the Clinical and Translational Science Institute (CTSI) at UCSF. Investigators at the San Francisco site of this multicenter trial received support from CTSI’s Clinical Research Services (CRS), including measurements of bone density and body composition and assistance with phlebotomy.
Dr. Mulligan, one of the co-authors of the paper, is director of the CRS Body Composition and Exercise Core, which is among the resources and services made available by CRS. In addition, a junior investigator from one of the international sites successfully completed the UCSF Masters in Clinical Research program, which is also supported by CTSI.
- Original article: "Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men."
CTSI at UCSF is a member of the national, NIH-funded CTSA network focusing on accelerating research to improve health. The Clinical Research Services is among a wide range of CTSI resources and services that support research at every stage.